ANTIBODY DRUG CONJUGATES MARKET OUTLOOK: TRENDS, TARGET POPULATION, COMPETITIVE LANDSCAPE, AND 2034 PROJECTIONS

Antibody-drug conjugates (ADCs) are an innovative development in cancer therapy, combining monoclonal antibodies with powerful cytotoxic drugs to deliver targeted treatment. This advanced technology improves the therapeutic effect while reducing systemic toxicity, making ADCs a transformative approach in oncology. With cancer rates rising globally